A hypothetical time course involving the neurotoxicity of Aβ and tau oligomers and mitochondrial dysfunction (Figure 2) can be used as a basis for the development of new AD drugs targeting pathophysiological processes in the initial stages of the disease. Here, MAPT is linked to Alzheimer disease.